LAG-3 Antibody Combination Therapies - Patent US12600777B2
Summary
The USPTO granted patent US12600777B2 to Novartis AG covering combination therapies comprising antibody molecules that specifically bind to LAG-3. The patent contains seven claims and relates to methods for treating, preventing, and/or diagnosing cancerous or infectious disorders. This represents a grant of exclusive intellectual property rights to Novartis AG for the therapeutic application of LAG-3 antibody combinations.
What changed
The USPTO issued patent US12600777B2 to Novartis AG on April 14, 2026, granting exclusive intellectual property rights for combination therapies comprising antibody molecules that specifically bind to LAG-3. The patent includes seven claims covering methods of treating cancerous or infectious disorders using these combination therapies. Inventors include Glenn Dranoff, Frederic Triebel, and others.\n\nFor pharmaceutical companies and biotechnology firms developing immunotherapy treatments, this patent establishes enforceable IP rights that may affect freedom-to-operate assessments for LAG-3 targeted combination therapies. Companies researching similar combination approaches should evaluate potential licensing requirements or design-around strategies.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Combination therapies comprising antibody molecules to LAG-3
Grant US12600777B2 Kind: B2 Apr 14, 2026
Assignee
Novartis AG
Inventors
Glenn Dranoff, Frederic Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Ann Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
Abstract
Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
CPC Classifications
C07K 16/2803 C07K 2317/24 C07K 2317/76 C07K 2317/92 A61P 35/00
Filing Date
2021-09-30
Application No.
17491420
Claims
7
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.